Tenax Therapeutics, Inc. (TENX)
NASDAQ: TENX · Real-Time Price · USD
4.770
-0.090 (-1.85%)
Nov 20, 2024, 4:00 PM EST - Market closed

Tenax Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2014
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2014
Selling, General & Admin
5.735.015.686.385.315.08
Upgrade
Research & Development
9.813.235.3825.154.563.47
Upgrade
Operating Expenses
15.548.2311.0531.539.878.56
Upgrade
Operating Income
-15.54-8.23-11.05-31.53-9.87-8.56
Upgrade
Interest Expense
-0.03-0.02-0-0-0-
Upgrade
Interest & Investment Income
0.52----0.14
Upgrade
Other Non Operating Income (Expenses)
0.490.550.010.020.030.02
Upgrade
EBT Excluding Unusual Items
-14.56-7.71-11.05-31.51-9.84-8.4
Upgrade
Gain (Loss) on Sale of Investments
----0.01-0.010
Upgrade
Gain (Loss) on Sale of Assets
-0-00---0
Upgrade
Other Unusual Items
----0.95--
Upgrade
Pretax Income
-14.56-7.71-11.05-32.47-9.85-8.39
Upgrade
Net Income
-14.56-7.71-11.05-32.47-9.85-8.39
Upgrade
Net Income to Common
-14.56-7.71-11.05-32.47-9.85-8.39
Upgrade
Shares Outstanding (Basic)
6000--
Upgrade
Shares Outstanding (Diluted)
6000--
Upgrade
Shares Change (YoY)
3389.71%1250.92%43.00%---
Upgrade
EPS (Basic)
-2.32-31.04-600.72-2525.03--
Upgrade
EPS (Diluted)
-2.32-31.04-600.72-2525.03--
Upgrade
Free Cash Flow
--5.9-11.39-10.86-9.28-7.56
Upgrade
Free Cash Flow Per Share
--23.76-619.37-844.53--
Upgrade
EBITDA
-15.53-8.23-11.05-31.52-9.86-8.55
Upgrade
D&A For EBITDA
0.010.010.01000.01
Upgrade
EBIT
-15.54-8.23-11.05-31.53-9.87-8.56
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.